Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 24, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results.
马萨诸塞州剑桥--(美国商业资讯)--2024年4月24日--罕见病精准遗传医学领域的领导者Sarepta Therapeutics, Inc.（纳斯达克股票代码：SRPT）将在纳斯达克全球市场于2024年5月1日星期三收盘后公布2024年第一季度财务业绩。随后，在美国东部时间下午 4:30，该公司将举行电话会议，讨论其2024年第一季度的财务业绩。
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
该活动将在Sarepta网站的投资者关系栏目下进行网络直播 https://investorrelations.sarepta.com/events-presentations 活动结束后，重播将在那里存档一年。通过电话参与的有兴趣的人士需要使用以下方式进行注册 这个在线表格。注册拨入详细信息后，所有电话参与者将收到一封自动生成的电子邮件，其中包含拨入号码的链接以及用于通过电话访问活动的个人 PIN 码。
About Sarepta Therapeutics
关于 Sarepta Therapeu
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
萨雷普塔正在执行一项紧急任务：为摧毁生命和缩短未来的罕见疾病设计精准遗传医学。我们在杜兴氏肌营养不良症（DMD）和肢节型肌营养不良症（LGMD）领域处于领导地位，目前我们有40多个项目处于不同的开发阶段。我们庞大的产品线由我们在基因治疗、RNA 和基因编辑领域的多平台精准遗传医学引擎驱动。欲了解更多信息，请访问 www.sarepta.com 或者关注我们 领英， X（前身为 Twitter）， Instagram 和 Facebook。
Internet Posting of Information
在互联网上发布信息
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
我们会定期在我们网站的 “投资者专区” 部分发布可能对投资者重要的信息，网址为www.sarepta.com。我们鼓励投资者和潜在投资者定期访问我们的网站以获取有关我们的重要信息。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424210170/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
投资者联系人：
伊恩·埃斯特潘，617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
媒体联系人：
特雷西·索伦蒂诺，617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
来源：Sarepta Therapeutics, Inc.
译文内容由第三方软件翻译。